Navigation Links
Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test
Date:5/1/2008

Interleukin 1B genetic patterns predict life-long tendency to inflammation

and related cardiovascular event risk profile

WALTHAM, Mass., May 1 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced publication of the results of clinical studies that support the company's Heart Health Genetic Test to assess cardiovascular risk. The article, titled, "IL1B Gene Promoter Haplotype Pairs Predict Clinical Levels of Interleukin-1beta and C-reactive Protein," was published in the journal Human Genetics (123:387-398; May 2008) and further confirms prior studies associating variations in the Interleukin 1B (IL1B) gene with the inflammatory response.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/ilgenetics/32863/

Sir Gordon W. Duff, M.D., Ph.D., one of the pioneers in the genetics of inflammatory diseases, was the senior author of the paper. Dr. Duff, former Director of the Division of Genomic Medicine, University of Sheffield, UK, commented, "It is now well recognized that inflammation is an underlying factor in many diseases including cardiovascular disease. Interleukin-1beta (IL-1beta) is a major regulator of inflammation. This paper from a collaborative team of international researchers, demonstrates that people with specific variation patterns in the IL1B gene had higher levels of IL-1beta and C-reactive protein (CRP). Studies from our group and others have found that these same IL1B gene variations were associated with an increased risk for cardiovascular disease and an increased risk for myocardial infarction at a younger age, that is, an early first heart attack."

The IL1B gene is among the first gene activated when the body encounters a challenge of almost any type, ranging from bacterial infections to bad cholesterol. IL-1beta initiates a complex cascade of related immune responses. Interleukin Genetics' approach, started over fifteen years ago, is to study variations in regulatory, or on/off switch, regions for these first mover genes and then link them to biological events and risk of inflammatory disease.

Dr. Kenneth Kornman, Chief Scientific Officer at Interleukin Genetics and an author on the paper explained the practical utility of the IL1B genetic information. "We use a simple cheek swab to collect an individual's DNA. Our technologists perform the genetic analysis in our CLIA certified laboratory. A report is generated about an individual's risk for excess inflammation and cardiovascular disease. The privacy-ensured report is sent directly to the individual, who then has access to physicians and genetic counselors to discuss results."

These peer-reviewed results build on prior studies which showed that three gene variations inherited together from a parent, called a haplotype, functioned together to control regulation of the gene producing IL-1beta. In this study, four specific IL1B haplotype pairs, one from each parent, representing just over half of the study population, were associated with higher tissue levels of IL-1beta levels, and two of those haplotype pairs were also associated with increased blood CRP levels. CRP is an inflammatory chemical that is well-established as an independent marker of risk for heart disease.

Interleukin Genetics' Heart Health Genetic Test is available to consumers in the U.S. and Canada under the Gensona(R) brand and marketed by Alticor Inc. The Gensona(R) Heart Health Genetic Test employs a number of single nucleotide polymorphisms (genetic sequence variations called SNPs) to identify specific genetic patterns in the Interleukin 1 genes. These genetic patterns are known to correlate with exaggerated inflammatory responses and increased risk of early cardiovascular disease. The Gensona(R) Heart Health Genetic Test is available in the Personalized Health Products category at Quixtar by e-mail at personalized.health.ca@quixtar.com. Quixtar also can be reached at 800-361-2213.

About Cardiovascular Disease

According to the Centers for Disease Control and Prevention, about 700,000 people die annually of cardiovascular disease. Cardiovascular disease involves the heart and vessels and is the number one killer in the U.S. accounting for nearly 30-percent of all deaths. Cardiovascular disease has a number of forms but the most common are myocardial infarction and angina pectoris which affect the heart itself. There are well known environmental risk factors associated with cardiovascular disease such as smoking, diet, inactivity and increased alcohol use. Heredity also plays a factor in cardiovascular disease since other risk factors like high blood pressure and high LDL cholesterol tend to run in families. Cardiovascular disease can be reduced by controlling environmental factors and understanding the genetic factors that put people at greater risk for heart disease.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2007 as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10- Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

Gensona(R) is a registered trademark of Alticor Inc. [Editors Note: Interleukin 1beta (IL-1beta) is the name for the protein,

whereas Interleukin 1B (IL1B) is the name of the gene.]


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
2. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
3. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Video: New Research Discovers Independent Brain Networks Control Human Walking
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... Australia Glaucoma Surgery Devices Market Outlook ... "Australia Glaucoma Surgery Devices Market Outlook to 2022", ... Surgery Devices market. The report provides value, in ... average prices (USD) within market segement - Glaucoma ... shares and distribution shares data for each of ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... at The Pierre Hotel in New York, NY, on December 3rd, to benefit ... and physicians attended the annual event, which raised over $1 million - the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
(Date:12/8/2016)... ... 2016 , ... Mirixa Corporation , a leading healthcare ... patient care services, has announced the promotions of Karen Litsinger to senior vice ... sales. , Litsinger joined Mirixa in 2008 after serving as a partner ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 , ... ... decreases in medical payments per workers’ compensation claim in 2013 and 2014, according to ... Workers Compensation Research Institute (WCRI) . , According to the study, medical payments per ...
Breaking Medicine News(10 mins):